The commercial opportunity is substantial, but national medicine spending is not the same as clinic-controlled procurement spend. The most relevant published annual benchmark is $41.6 billion in US spending on GLP-1 antiobesity medicines in 2025, measured using pharmaceutical purchase data—not revenue earned by weight-management clinics. The study was published on April 30, 2026. AJHP expenditure study (academic.oup.com)
Three developments should shape the next supplier decision:
- Demand growth and price pressure are happening together. Lilly reported US Zepbound revenue growth of 48% in Q3 2026, while explicitly identifying lower realized prices as an offset to demand. A growing market does not establish that a clinic can preserve yesterday’s pricing or margin. Lilly, October 29, 2026
- Branded access is becoming more integrated into telehealth. Lilly and Hims & Hers announced an integrated access agreement on November 6, 2026; LifeMD disclosed dispensing arrangements with both major manufacturers on November 12. These are access and fulfillment developments, not evidence of an available wholesale discount for every clinic. Hims & Hers announcement; LifeMD results
- The next budget crosses a documented pricing change. Novo Nordisk announced a $675 monthly wholesale acquisition cost, effective January 1, 2027, for specified semaglutide products. That date is in the future relative to this report, and the announcement explicitly distinguishes the list-price change from direct-to-patient self-pay prices. Novo Nordisk, February 24, 2026
Procurement recommendation: compare lawful access routes using matched product, presentation, eligibility, days supplied and service obligations. Do not treat a patient offer as a clinic acquisition quote, or an announced partnership as guaranteed capacity.
Sources cited on this page
- academic.oup.com · Source 1 ↗https://academic.oup.com/ajhp/article/83/14/728/8662887
- academic.oup.com · Source 2 ↗https://academic.oup.com/ajhp/article/83/14/728/8662887?login=true&utm_source=openai
- lilly.gcs-web.com · Source 3 ↗https://lilly.gcs-web.com/node/55191/pdf
- investors.hims.com · Source 4 ↗https://investors.hims.com/news/news-details/2026/Lilly-and-Hims--Hers-expand-access-to-FDA-approved-Lilly-medicines/default.aspx
- sec.gov · Source 5 ↗https://www.sec.gov/Archives/edgar/data/948320/000149315226051397/ex99-1.htm
- novonordisk-us.com · Source 6 ↗https://www.novonordisk-us.com/media/press-releases/novo-nordisk-lowers-wegovy-ozempic-list-price.html